Recently, pharmaceutical manufacturer, Mylan NV came under fire for dramatically raising the cost of EpiPen, a life saving allergy medication. The statements they released following the criticism sent mixed messages. How could Mylan have handled themselves better? Tom Faust, managing director at Stanton, shared his thoughts in Wall Street Journal’s “Crisis of the Week”.

Read the article here